Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Schaad, Heinz J ^b   Bento, Manuela ^a   Lew, Daniel P ^a   Vaudaux, Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Spital Interlaken ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; DAPTOMYCIN; METICILLIN; OXACILLIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CATHETER INFECTION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOREIGN BODY REACTION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RAT; SEPSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FOREIGN BODIES; MICROBIAL SENSITIVITY TESTS; OXACILLIN; RATS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 33646566315     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-74     Document Type: Article

References (47)

1. Waldvogel FA, Bisno AL: Infections associated with indwelling medical devices 3rd edition. Edited by: Waldvogel FA and Bisno AL. Washington, DC, American Society for Microbiology, 2000: 1-436.
2. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M, SENTRY PG: Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32:S114-S132.
3. Lowy FD: Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 2003, 111:1265-1273.
4. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001, 7:178-182.
5. Hiramatsu K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001, 1:147-155.
6. Liu C, Chambers HF: Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003, 47:3040-3045.
7. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003, 348:1342-1347.
8. Carpenter CF, Chambers HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004, 38:994-1000.
9. Steenbergen JN, Alder J, Thorne GM, Tally FP: Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005, 55:283-288.
10. Hancock RE: Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005, 5:209-218.
11. Schriever CA, Fernandez C, Rodvold KA, Danziger LH: Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 2005, 62:1145-1158.
12. Tally FP, DeBruin MF: Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000, 46:523-526.
13. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
14. Silverman JA, Perlmutter NG, Shapiro HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:2538-2544.
15. King A, Phillips I: The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001, 48:219-223.
16. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM: Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000, 44:3447-3450.
17. Barry AL, Fuchs PC, Brown SD: In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001, 45:1919-1922.
18. Wise R, Andrews JM, Ashby JP: Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001, 48:563-567.
19. Hanberger H, Nilsson LE, Maller R, Isaksson B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 1991, 35:1710-1716.
20. Fuchs PC, Barry AL, Brown SD: In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002, 49:467-470.
21. Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004, 48:63-68.
22. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL: Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2001, 45:845-851.
23. Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP: Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003, 52:405-411.
24. Kennedy S, Chambers HF: Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob Agents Chemother 1989, 33:1522-1525.
25. Cantoni L, Glauser MP, Bille J: Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob Agents Chemother 1990, 34:2348-2353.
26. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1990, 34:2081-2085.
27. Voorn GP, Kuyvenhoven J, Goessens WH, Schmal-Bauer WC, Broeders PH, Thompson J, Michel MF: Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother 1994, 38:487-493.
28. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J: Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005, 191:2149-2152.
29. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD: Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003, 47:1318-1323.
30. Oleson FBJ, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000, 44:2948-2953.
31. Tally FP, Zeckel ML, Wasilewski M, Carini C, Berman CL, Drusano GL, Oleson FBJ: Daptomycin: a novel agent for Gram-positive infections. Experimental Opinion on Investigational Drugs 2001, 8:1223-1238.
32. Lucet JC, Herrmann M, Rohner P, Auckenthaler R, Waldvogel FA, Lew DP: Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990, 34:2312-2317.
33. Schaad HJ, Chuard C, Vaudaux P, Rohner P, Waldvogel FA, Lew DP: Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin- susceptible and -resistant Staphylococcus aureus. J Antimicrob Chemother 1994, 33:1191-1200.
34. Schaad HJ, Chuard C, Vaudaux P, Waldvogel FA, Lew DP: Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994, 38:1703-1710.
35. Cagni A, Chuard C, Vaudaux P, Schrenzel J, Lew DP: Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicilin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995, 39:1655-1660.
36. Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew DP: Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002, 46:1503-1509.
37. Vaudaux P, Francois P, Bisognano C, Li D, Lew DP, Schrenzel J: Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 2003, 52:89-95.
38. Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP: Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:3789-3793.
39. Vaudaux P, Schaad H, Francois P, Bisognano C, Chuard C, Schrenzel J, Lew D: Efficacy of a high dose regimen of daptomycin compared to oxacillin and vancomycin in the therapy of experimental foreign body infection due to methicillin-susceptible Staphylococcus aureus. 42nd Intersci Conf Antimicrob Agents Chemother, San Diego, CA 2002:Abstract B-274.
40. Fowler, V., Cosgrove, S., Abrutyn E, Boucher, H., Chambers, H., Corey, G., Demeyer, I., Filler, S., Levine, D., Link, A., Rupp, M., Karchmer, A.: Daptomycin vs. standard therapy for Staphylococcus aureus bacteremia and infective endocarditis. 45th Intersci Conf Antimicrob Agents Chemother, Washington, DC 2005:Abstract K-426a.
41. Benvenuto, M., Benziger, D., Yankelev, S., Summers, E., Vigliani, G.: Safety and pharmacokinetics of daptomycin at doses up to 12 mg/kg daily. 45th Intersci Conf Antimicrob Agents Chemother, Washington DC 2005:Abstract LB-2.
42. Rouse MS, Piper KE, Jacobson, M.J., Steckelberg JM, Patel R: Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. 45th Intersci Conf Antimicrob Agents Chemother, Washington, DC 2005:Abstract B-2008.
43. Chuard C, Lucet JC, Rohner P, Herrmann M, Auckenthaler R, Waldvogel FA, Lew DP: Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 1991, 163:1369-1373.
44. Clinical and Laboratory Standards Institute (CLSI): Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th. ed. Approved Standard. CLSI document M7-A6, Vol. 23. Volume 6th. ed. Approved Standard. Edited by: CLSI. Wayne, Pa.; 2003.
45. Rosner B: Fundamentals of biostatistics 3rd edition. Belmont, CA, Duxbury Press; 1990:1-655.
46. Bouchenaki N, Vaudaux P, Huggler E, Waldvogel FA, Lew DP: Successful single-dose prophylaxis of Staphylococcus aureus foreign body infection in guinea pigs by fleroxacin. Antimicrob Agents Chemother 1990, 34:21-24.
47. Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT: Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:1714-1718.